International ID Day: Thales Stands up for a Legal and Trusted Identity for Everyone
16.9.2024 08:00:00 CEST | Business Wire | Press release
On the International Identity Day ‘ID Day’, Thales reaffirms its dedication to supporting global identity initiatives and driving technological advancements that foster inclusion, security, and trust. Around the world, more than 850 million individuals do not have a legal identity, preventing them from claiming their rights and accessing fundamental citizen services e.g. health, education, employment. Thales has been working for more than thirty years to make trustworthy identities a reality for everyone, employing cutting-edge and responsible technology for biometrics and digital ID solutions.
On September 16th, Thales celebrates the International Identity Day (ID Day), a symbolic day to highlight the United Nations' Sustainable Development Goal16.9 to provide a legal identity for all. ID Day is dedicated to raising awareness about the importance of legal identity as a fundamental human right and a key enabler of inclusive social and economic development. Thales supports global efforts to guarantee every individual has access to a secure and trusted identity.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240915417415/en/
(Photo: Thales)
Thales, a leading provider of secure physical and biometrics identification, has been actively involved in projects that are in line with the UN's Sustainable Development Goal 16.9, including birth registration, by 2030. According to the 2023 estimates from the World Bank's Identification for Development (ID4D) Initiative, over 850 million people globally lack an official ID. Thanks to global mobilization, the overall situation has improved since 2020 when 1 billion individuals were missing a legal ID.
ID Day highlights the significance of having a legal identity and the positive impact it has on individuals and communities worldwide. A legal identity grants access to essential services, fosters social inclusion, and facilitates participation in the global economy. That is why Thales, recognised as the number one digital identity player by Juniper Research (in its “2024 Juniper Research Competitor Leaderboard”) stands for a future in which everyone could benefit from and confirm their trusted identity, leaving no one behind.
"ID Day serves as a crucial reminder that identity is a fundamental human right. In today's interconnected world, having a secure and trusted legal ID is essential for accessing services, exercising rights, and fostering economic development. At Thales, we are committed to driving innovation in biometric and digital identity solutions, ensuring that every individual can claim their rightful place in society. Our goal is to support with our solutions a world where identity is secure, inclusive, and universally recognized," said Youzec Kurp, VP Identity and Biometrics Solutions at Thales Group.
A secure identity is more than just a document; it is a gateway to opportunities and a cornerstone of trust in the digital age. Thales responsible biometrics (cfTrUE Biometrics1) and digital ID solutions are designed to meet the highest security standards, protecting individuals' personal data while facilitating seamless access to services as well as mobility.
1TrUE Biometrics stands for Transparent, Understandable and finally Ethical. For years, Thales has developed highly secure solutions and biometrics has proved its full capacity to offer both security and convenience. While the technology serves a wide range of new needs triggered by our societies' digital transformation, Thales also supports initiatives that raise awareness of the benefits and risks of adopting biometric identification technologies. Thales is a reliable and responsible partner since it provides transparent, understandable, and ethical biometrics.
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies specialized in three business domains: Defence & Security, Aeronautics & Space, and Cybersecurity & Digital identity.
It develops products and solutions that help make the world safer, greener and more inclusive.
The Group invests close to €4 billion a year in Research & Development, particularly in key innovation areas such as AI, cybersecurity, quantum technologies, cloud technologies and 6G.
Thales has close to 81,000 employees in 68 countries. In 2023, the Group generated sales of €18.4 billion.
PLEASE VISIT
Thales Group
Digital Identity & Security
Thales
Thales Digital Identity and Security
View source version on businesswire.com: https://www.businesswire.com/news/home/20240915417415/en/
Contacts
PRESS CONTACTThales, Media Relations
PRESS CONTACTThales, Media Relations
Digital Identity and Security
Vanessa Viala
+33 (0)6 07 34 00 34
vanessa.viala@thalesgroup.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datavault AI Announces Board of Directors Has Requested Management’s Complete Plan for Dividend Spin-Out of Acoustic Sciences Division into Stand-Alone Public Company7.5.2026 15:07:00 CEST | Press release
Initial planning calls for Data Sciences Division to focus efforts in cyber secure infrastructure with dedication in fintech and patented Information Data Exchange® (IDE®) Management will harness its API Media acquisition, robust patent portfolio, ADIO® Inaudible Tones, WiSA® and Dolby® partnerships to establish worldwide acoustic industry standards in high-definition wireless transmission, spatial-audio control and interoperability Plan includes API media’s stand-alone and renewed execution of WiSA semiconductor and software modules strategy with an R&D effort targeted to new robotic and drone applications Datavault AI Inc. (“Datavault AI” or the “Company”) (NASDAQ:DVLT), a pioneering technology licensing company seeking to redefine data valuation, monetization, and secure Web 3.0 experiences, today announced that Company management has commenced its evaluation of a potential dividend spin-out of the Company’s Acoustic Sciences division which includes its ADIO®, WiSA®, Event Citadel™,
Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis7.5.2026 14:50:00 CEST | Press release
First presentation of Week 24 results from TRuE-AD4 study in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs)at the 2026 EADV SymposiumThe vast majority of patients achieving EASI50 at Week 8 and continuing double-blind, as needed treatment with Opzelura® (ruxolitinib) cream through Week 24 demonstrated disease control, with 84.3% achieving EASI75 (a ≥75% improvement in the Eczema Area and Severity Index score from baseline) and 70.6% achieving IGA-TS (Investigator’s Global Assessment Treatment Success)Data support Type-II variation application submitted for ruxolitinib cream 1.5% for the treatment of adults with moderate AD in the European Union (EU), feedback expected in 1H 2026 Incyte (Nasdaq:INCY) today announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib) cream in adults with mode
Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 14:03:00 CEST | Press release
Full data presented at ESOC 2026 further strengthen the clinical evidence supporting TIGERTRIEVER™ 13 for the treatment of distal vessel occlusion stroke — a segment representing nearly half of all ischemic strokes Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L
2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 14:00:00 CEST | Press release
“Eat Where Locals Eat” Making authentic Japanese dining experiences accessible to global travelers through instant reservations at over 70,000 restaurants nationwide. Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 14:00:00 CEST | Press release
Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom